Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis

BackgroundEvidence regarding the mortality benefit of implantable cardioverter defibrillator (ICD) non-ischemic dilated cardiomyopathy (NIDCM) is inconsistent. The most recent randomized study, the DANISH trial, did not find improved outcomes with ICD. However, based on previous studies and meta-ana...

詳細記述

書誌詳細

主要な著者:	Yotam Kolben, Bruria Hirsh Raccah, Ivelin Koev, David Luria, Offer Amir, Yitschak Biton
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2023-05-01
シリーズ:	Frontiers in Cardiovascular Medicine
主題:	ICD (implantable cardioverter-defibrillator) NIDCM SGLT 2 inhibitors ARNI angiotensin receptor neprilysin inhibitor sudden cardiac death (SCD)
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fcvm.2023.1192101/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!